drugset
drugset / Trial / NCT04188509

Open-Label Extension of Voxelotor

NCT04188509 ↗

Phase 3 Terminated 162 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

Open-label extension study of voxelotor for participants with Sickle Cell Disease who have participated in voxelotor clinical trials.

Timeline

Start
2019-11-18
Primary completion
2024-11-01
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Voxelotor Small molecule 1500 mg Oral

Indications

sickle cell disease